The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis: a two-center prospective cohort study-Reference-Cited by-同舟云学术

The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis: a two-center prospective cohort study

Published:2023-05-02 Issue:1 Volume:34 Page:
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Bosma Angela L.¹^ORCID,Gerbens Louise A. A.¹^ORCID,El Khattabi Hajar¹^ORCID,Loeff Floris C.²^ORCID,Duckworth Michael³^ORCID,Woolf Richard T.⁴^ORCID,Rispens Theo⁵^ORCID,Smith Catherine H.³⁴^ORCID,Spuls Phyllis I.¹^ORCID

Affiliation:

1. Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands

2. Sanquin Diagnostic Services, Amsterdam, The Netherlands

3. St John’s Institute of Dermatology, School of Basic and Medical Biosciences, King’s College London, London, UK

4. St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

5. Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2023.2193663

Reference36 articles.

1. Dupixent. Summary of product characteristics. 2017 [cited 2021 Feb 26]. Available from: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf

2. Dupixent. European public assessment report. 2017 [cited 2020 Sep 29]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/dupixent-epar-public-assessment-report_en.pdf

3. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

4. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis

5. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study